Literature DB >> 11750164

Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.

D J Keele1, V C DeLallo, R E Lewis, E J Ernst, M E Klepser.   

Abstract

In this study, time-kill methods were used to evaluate the antifungal activity of amphotericin B and flucytosine, alone and in combination, against six isolates of Candida albicans and Cryptococcus neoformans. Five regimens were tested against each isolate: (1) flucytosine, (2) low-dose amphotericin B, (3) high-dose amphotericin B, (4) low-dose amphotericin B plus flucytosine, and (5) high-dose amphotericin B plus flucytosine. Low-dose amphotericin B and flucytosine, administered alone and simultaneously, demonstrated fungistatic activity against all sample isolates except C. albicans 90028, in which fungicidal activity was detected with the combination. High-dose amphotericin B, alone and in combination, resulted in a rapid fungicidal effect in all isolates. In both the low and high-dose combinations, indifferent activity was demonstrated against all tested isolates. By virtue of the absence of an antagonistic interaction between these two agents, complementary pharmacokinetic profiles, and non-overlapping toxicities, continued clinical use of these agents in combination may be considered.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11750164     DOI: 10.1016/s0732-8893(01)00297-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

1.  In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 3.  Antifungal therapy for newborn infants with invasive fungal infection.

Authors:  Linda Clerihew; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

4.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 6.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Innovation of natural essential oil-loaded Orabase for local treatment of oral candidiasis.

Authors:  Gihan S Labib; Hibah Aldawsari
Journal:  Drug Des Devel Ther       Date:  2015-06-29       Impact factor: 4.162

8.  Successful treatment of Batrachochytrium salamandrivorans infections in salamanders requires synergy between voriconazole, polymyxin E and temperature.

Authors:  M Blooi; F Pasmans; L Rouffaer; F Haesebrouck; F Vercammen; A Martel
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

9.  De Novo Pyrimidine Biosynthesis Connects Cell Integrity to Amphotericin B Susceptibility in Cryptococcus neoformans.

Authors:  Dithi Banerjee; Timothy C Umland; John C Panepinto
Journal:  mSphere       Date:  2016-11-16       Impact factor: 4.389

Review 10.  Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.

Authors:  Anne-Laure Bidaud; Patrick Schwarz; Guillaume Herbreteau; Eric Dannaoui
Journal:  J Fungi (Basel)       Date:  2021-02-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.